Safety, Tolerability and Pharmacokinetic-Pharmacodynamic Relationship of NX210c Peptide in Healthy Elderly Volunteers: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study
Multiple doses of NX210c exhibited a good safety profile, showed non-cumulative pharmacokinetics, and exerted pharmacodynamic effects on biomarkers linked to BBB integrity. The effects of NX210c on claudin-5 and biomarkers influencing BBB integrity-and the overarching brain protection it offers-provide a novel therapeutic strategy targeting an underlying driver of neurodegenerative conditions for which disease-modifying treatments are limited or not available.
Authors
- Philip H. C. Kremer (ORCID: https://orcid.org/0000-0003-0483-841X)
- Annette Janus (ORCID: https://orcid.org/0009-0001-4894-9608)
- Sébastien Marie
- Yann Godfrin
- Juliette Le Douce
- Giuseppe Pasculli (ORCID: https://orcid.org/0000-0002-0499-2292)
- Sighild Lemarchant (ORCID: https://orcid.org/0000-0001-8671-9099)
- Dominique Dumas (ORCID: https://orcid.org/0000-0002-2786-9633)
- Pauline Bambury
Institutions
- Leiden University Medical Center (NL)
- Xerox (France) (FR)
- Centre for Human Drug Research (NL)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1007/s40120-024-00691-w
- Citations
- 4
- Primary Topic
- Barrier Structure and Function Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.99